Goldman Sachs Group Inc Catalyst Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 3,135,473 shares of CPRX stock, worth $76.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,135,473

Previous 2,802,373 11.89%

Holding current value

$76.2 Million

Previous $58.5 Million 30.01%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 09, 2025	BUY	$19.53 - $25.74 $6.51 Million - $8.57 Million	333,100 Added 11.89%	3,135,473 $76 Million
Q4 2024 Feb 11, 2025	BUY	$19.73 - $23.93 $26.2 Million - $31.8 Million	1,330,120 Added 90.35%	2,802,373 $58.5 Million
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $5.83 Million - $8.2 Million	384,122 Added 35.3%	1,472,253 $29.3 Million
Q2 2024 Aug 13, 2024	BUY	$14.68 - $16.92 $1.27 Million - $1.47 Million	86,850 Added 8.67%	1,088,131 $16.9 Million
Q1 2024 May 15, 2024	BUY	$13.18 - $17.11 $565,000 - $733,471	42,868 Added 4.47%	1,001,281 $16 Million
Q4 2023 Feb 13, 2024	SELL	$11.78 - $17.29 $116,692 - $171,274	-9,906 Reduced 1.02%	958,413 $16.1 Million
Q3 2023 May 14, 2024	BUY	$11.69 - $15.02 $115,801 - $148,788	9,906 Added 1.03%	968,319 $11.3 Million
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $3.3 Million - $4.24 Million	-282,209 Reduced 22.57%	968,319 $11.3 Million
Q2 2023 May 14, 2024	BUY	$11.5 - $18.08 $1.31 Million - $2.06 Million	113,791 Added 10.01%	1,250,528 $16.8 Million
Q2 2023 Aug 14, 2023	BUY	$11.5 - $18.08 $1.31 Million - $2.06 Million	113,791 Added 10.01%	1,250,528 $16.8 Million
Q1 2023 May 14, 2024	BUY	$14.34 - $21.05 $5.35 Million - $7.85 Million	372,774 Added 48.79%	1,136,737 $18.8 Million
Q1 2023 May 11, 2023	BUY	$14.34 - $21.05 $5.35 Million - $7.85 Million	372,774 Added 48.79%	1,136,737 $18.8 Million
Q4 2022 May 14, 2024	BUY	$12.25 - $19.5 $537,003 - $854,821	43,837 Added 6.09%	763,963 $14.2 Million
Q4 2022 Feb 13, 2023	BUY	$12.25 - $19.5 $537,003 - $854,821	43,837 Added 6.09%	763,963 $14.2 Million
Q3 2022 May 14, 2024	SELL	$7.06 - $15.52 $8.41 Million - $18.5 Million	-1,190,538 Reduced 62.31%	720,126 $9.24 Million
Q3 2022 Nov 10, 2022	SELL	$7.06 - $15.52 $8.41 Million - $18.5 Million	-1,190,538 Reduced 62.31%	720,126 $9.24 Million
Q2 2022 May 14, 2024	BUY	$6.23 - $8.57 $5.93 Million - $8.16 Million	952,251 Added 99.36%	1,910,664 $13.4 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $5.03 Million - $6.92 Million	807,303 Added 73.17%	1,910,664 $13.4 Million
Q1 2022 May 16, 2022	BUY	$5.31 - $8.31 $2.03 Million - $3.17 Million	381,435 Added 52.84%	1,103,361 $9.15 Million
Q4 2021 Feb 14, 2022	BUY	$5.21 - $7.45 $36,829 - $52,664	7,069 Added 0.99%	721,926 $4.89 Million
Q3 2021 Nov 10, 2021	BUY	$4.85 - $6.04 $3.47 Million - $4.32 Million	714,857 New	714,857 $3.79 Million

Others Institutions Holding CPRX

# of Institutions

364

Shares Held

95.5M

Call Options Held

13.4K

Put Options Held

11.7K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.5B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Catalyst Pharmaceuticals, Inc. Transaction History